On 16 July, the “Talent meets industry in the Yangtze estuary” Nantong biopharmaceutical cooperation event was held in Shanghai, jointly hosted by the Organisation Department (Talent Office) of the Nantong Municipal Party Committee, the Nantong Municipal Administration for Market Regulation and Nantong Industry Holding Group.
As one of the emerging players in biopharmaceuticals, Westlake Pharmaceuticals was invited to attend and, at the signing ceremony, formally signed strategic cooperation agreements with the Nantong Industry Holding Siyuan AI Pioneer Fund and the Nantong Haorui Venture Investment Partnership. The signing brings substantial capital momentum and marks the company’s entry into cross-regional industrial collaboration.
The event aimed to deepen industrial co-development between Shanghai and Nantong and to help biopharmaceutical innovations cross the Yangtze into commercial deployment. Ling Li, Deputy Mayor of Nantong; Shuai Shao, Vice President of Shanghai Pharmaceuticals; and other officials, industry experts, investors and company representatives discussed the upgrading of the biopharmaceutical industry across the Yangtze River Delta.
The convergence of life sciences and artificial intelligence is reshaping the pharmaceutical landscape. The agreements reflect the two Nantong funds’ recognition of Westlake Pharmaceuticals’ work in frontier technology and its ability to translate research into business.
Since its founding in 2020, Westlake Pharmaceuticals has focused on original drug discovery, integrating artificial intelligence with multiple disciplines of pharmaceutical research to upgrade the drug discovery paradigm.
Building on this agreement, and supported by capital and industrial policy, the company will continue to increase investment in R&D. Westlake Pharmaceuticals looks forward to working closely with its investors, integrating into Nantong’s pharmaceutical ecosystem, and accelerating the translation of frontier research into therapies for patients.